Revenue $4.4 billion up 25.2 per cent and underlying EBITDA is up 13.4 per cent to $149.0 million.
EBOS Chief Executive Officer, John Cullity said: “Our strong results are reflective of the commencement of the Chemist Warehouse Group (CWG) pharmaceutical wholesale contract, together with strong performances from our Institutional Healthcare, Contract Logistics and TerryWhite Chemmart (TWC) Group businesses.
Shares in EBOS (ASX:EBO) closed 1.5 per cent lower at $22.40 yesterday.